NCT01246063 · REGISTRY CONDITION SEARCH

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2019-04-08

The aim of this phase I/II trial is to determine the maximal tolerated dose (MTD) of carfilzomib together with pegylated liposomal doxorubicin hydrochloride (PLD) with or without dexamethasone, and then to establish the efficacy and safety of this novel combination in patients with relapsed or refractory multiple myeloma

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1).

→

outcome · POSTED

Maximum Tolerated Dose (MTD) of Carfilzomib and PLD (Phase I - Part 2).

→

outcome · POSTED

Maximum Tolerated Dose (MTD) of Dexamethasone (Phase I - Part 2).

→

outcome · POSTED

Phase 2 - Efficacy of Carfilzomib in Combination With PLD and Dexamethasone as Measured by the Percentage of Participants With Confirmed Tumor Responses

→

outcome · POSTED

Phase 2 - Toxicity of Carfilzomib in Combination With PLD and Dexamethasone as Measured by Number of Participants Who Experience Grade 3/4 Toxicity

→

outcome · POSTED

Median Overall Survival

→

outcome · POSTED

Progression-free Survival Time (Phase 2 Only)

→

outcome · POSTED

Median Duration of Overall Response

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically confirmed diagnosis of multiple myeloma with a measurable disease parameter at time of screening; a measurable disease parameter is defined as one or more of the following: * Serum monoclonal protein \>= 0.5 g/dl * 24 hour urine monoclonal protein \>= 0.2 g/24 hour * Serum free light chain ratio \> 5 x normal ratio with an absolute difference of 10mg/dl between the involved and uninvolved free light chain * Soft tissue plasmacytoma \>= 2 cm measurable by either physical examination and/or applicable radiographs (e.g. magnetic resonance imaging \[MRI\], computed tomography \[CT\], etc) * Bone Marrow Plasma Cells \>= 30% * Documentation of at least one line of prior myeloma therapy now with relapsed or refractory disease requiring re-treatment * At least 18 years of age at the time of signing the informed consent. * Performance status of Eastern Cooperative Oncology Group (ECOG) =\< 2 or Karnofsky \>= 60%; participants with lower performance status based solely on bone pain secondary to multiple myeloma will be eligible * Required laboratory values * Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) and aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) \< 2.5 x the upper limit of the institutional normal value (ULN) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * Absolute neutrophil count (ANC) \>= 1,000 * Hemoglobin \>= 8 g/dl * Platelets \>= 50,000 * Creatinine clearance \> 15 ml/minute using Cockcroft-Gault formula * For those participants receiving warfarin (Coumadin), unfractionated heparin, or low-molecular weight heparin therapy, the applicable coagulation parameter that is being monitored must be within the accepted therapeutic ranges for those indications * Transfusions and/or growth factor dependent participants are not excluded if the above parameters can be achieved with such support * Females of childbearing potential (FCBP) must agree to refrain from becoming pregnant while on study drug and for 3 months after discontinuation from study drug, and must agree to use adequate contraception including hormonal contraception, (i.e. birth control pills, etc), barrier method contraception (i.e. condoms), or abstinence during that time frame; FCBP must agree to regular pregnancy testing during this timeframe; inclusion of FCBP requires two negative pregnancy tests prior to enrollment. All women, regardless of age, should be considered FCBP unless they are surgically sterile (post hysterectomy, post bilateral oophorectomy, etc) or have been naturally post menopausal for \>= 24 consecutive months * Men engaging in sexual intercourse with a FCBP must agree to use adequate contraception including hormonal contraception, (i.e. birth control pills, etc), barrier method contraception (i.e. condoms), or abstinence while on study drug and for 3 months after discontinuation from study drug * Ability to understand and willing to sign a written informed consent document Exclusion Criteria: * POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) * Plasma Cell Leukemia * Waldenstrom's macroglobulinemia * Pregnant or lactating females * Use of any anti-myeloma drug therapy within 14 days of initiation of study drug treatment excluding corticosteroids if given for an indication other than myeloma; bisphosphonates are not considered anti-myeloma drugs * Participation in an investigational therapeutic study within 14 days of initiation of study drug treatment * Radiotherapy to multiple sites or immunotherapy within 14 days of initiation of study drug treatment (localized radiotherapy to a single site at least 7 days before start is permissible) * Major surgery within 14 days of initiation of study drug treatment * Participants in whom the required program of oral (PO) and IV fluid hydration is contraindicated * Prior history of a hypersensitivity reaction to PLD, doxorubicin, bortezomib, carfilzomib, or liposomal drug formulations other than PLD; history of reactions to liposomal drug formulations other than PLD should be evaluated individually and if their reactions were felt to have been due to the encapsulated agent, rather than the liposomal component itself they should be excluded at the discretion of the investigators * Participants who are known to have active hepatitis A, B, or C viral infection may not participate in this study; active disease is defined as participants with a known viral hepatitis whose liver function tests are elevated * Known human immunodeficiency virus (HIV)-seropositive and are taking anti-retrovirals may not participate in this study; participants who are HIV-seropositive and not on anti-retroviral therapy and who otherwise meet the inclusion/exclusion criteria will be eligible for the study * Compromised cardiovascular function defined as any of the following: * Electrocardiogram (EKG) evidence of acute ischemia * EKG evidence of medically significant conduction system abnormalities * History of myocardial infarction within the last 6 months * Unstable angina pectoris or cardiac arrhythmia * History of Class 3 or Class 4 New York Heart Association Congestive Heart Failure within 6 months of enrollment on study * Left ventricular ejection fraction (LVEF) \< 45% by either echocardiography or radionuclide-based multiple gated acquisition (Echo or MUGA) * Uncontrolled concurrent illness including: other hematologic or non-hematologic malignancy, active infection, or uncontrolled diabetes * Any significant psychological, medical, or surgical condition thought to compromise the participant, the study, or prevent informed consent
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Dose Level 0: Carfilzomib IV (20 mg/m\^2) D1\&D2 of C1 and carfilzomib IV (27 mg/m\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\^2)D8 C1-6.
intervention Names
Drug: carfilzomib
Drug: pegylated liposomal doxorubicin (PLD)
label
Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)
type
EXPERIMENTAL
description
Dose Level 1: Carfilzomib IV (20 mg/m\^2) D1\&D2 of C1 and carfilzomib IV (36 mg/m\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\^2)D8 C1-6. Dose Level 1: Carfilzomib IV (1 dose level above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (1 dose level above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (1 dose level above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib. Dose Level 2: Carfilzomib IV (2 dose levels above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (2 dose levels above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (2 dose levels above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
intervention Names
Drug: carfilzomib
Drug: pegylated liposomal doxorubicin (PLD)
label
Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)
type
EXPERIMENTAL
description
Dose Level 2: Carfilzomib IV (20 mg/m\^2) D1\&D2 of C1 and carfilzomib IV (45 mg/m\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\^2)D8 C1-6.
intervention Names
Drug: carfilzomib
Drug: pegylated liposomal doxorubicin (PLD)
label
Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)
type
EXPERIMENTAL
description
Dose Level 3: Carfilzomib IV (20 mg/m\^2) D1\&D2 of C1 and carfilzomib IV (56 mg/m\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\^2)D8 C1-6.
intervention Names
Drug: carfilzomib
Drug: pegylated liposomal doxorubicin (PLD)
label
Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)
type
EXPERIMENTAL
description
Cohort 0: Carfilzomib IV (56 mg/\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
intervention Names
Drug: carfilzomib
Drug: pegylated liposomal doxorubicin (PLD)
Drug: Dexamethasone
label
Phase I -Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)
type
EXPERIMENTAL
description
Carfilzomib IV (56 mg/\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
intervention Names
Drug: carfilzomib
Drug: pegylated liposomal doxorubicin (PLD)
Drug: Dexamethasone
label
Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)
type
EXPERIMENTAL

interventions

arm Group Labels
Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)
Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)
Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)
Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)
Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)
Phase I -Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)
name
carfilzomib
other Names
Kyprolis
CFZ
type
DRUG
arm Group Labels
Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)
Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)
Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)
Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)
Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)
Phase I -Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)
name
pegylated liposomal doxorubicin (PLD)
other Names
DOXIL
type
DRUG
arm Group Labels
Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)
Phase I -Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)
name
Dexamethasone
other Names
Decadron
type
DRUG

Study design

allocation

NON_RANDOMIZED

intervention Model

SEQUENTIAL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 40
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
* MTD is the maximum tolerated dose level tested unless dose limiting toxicity (DLT) are observed during Cycle 1. If DLT is observed, MTD will be the next lower dose level. * Please note that the maximum tolerated dose of carfilzomib and pegylated liposomal doxorubicin was not reached. The data below is the recommended dosage for further studies.
measure
Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1).
time Frame
28 days (completion of first cycle of all Phase I - Part 1 patients)
description
-MTD is the maximum tolerated dose level tested unless dose limiting toxicity (DLT) are observed during Cycle 1. If DLT is observed, MTD will be the next lower dose level.
measure
Maximum Tolerated Dose (MTD) of Carfilzomib and PLD (Phase I - Part 2).
time Frame
28 days (completion of first cycle of all Phase I - Part 2 patients)
description
-MTD is the maximum tolerated dose level tested unless dose limiting toxicity (DLT) are observed during Cycle 1. If DLT is observed, MTD will be the next lower dose level.
measure
Maximum Tolerated Dose (MTD) of Dexamethasone (Phase I - Part 2).
time Frame
28 days (completion of first cycle of all Phase I - Part 2 patients)
description
-A confirmed response is defined to be a complete response (CR), very good partial response (VGPR), or partial response (PR) per IMWG Criteria.
measure
Phase 2 - Efficacy of Carfilzomib in Combination With PLD and Dexamethasone as Measured by the Percentage of Participants With Confirmed Tumor Responses
time Frame
Completion of treatment (median number of cycles was 9.5 (range 1-34))
measure
Phase 2 - Toxicity of Carfilzomib in Combination With PLD and Dexamethasone as Measured by Number of Participants Who Experience Grade 3/4 Toxicity
time Frame
Through 30 days after completion of treatment (median number of cycles was 9.5 (range 1-34))

secondary Outcomes

measure
Median Overall Survival
time Frame
Completion of follow-up (median of 23.3 months)
description
-Progression per IMWG Criteria
measure
Progression-free Survival Time (Phase 2 Only)
time Frame
Through completion of follow-up (median follow-up was 23.3 months)
description
* For participants with confirmed tumor responses * A confirmed response is defined to be a complete response (CR), very good partial response (VGPR), or partial response (PR) per IMWG Criteria
measure
Median Duration of Overall Response
time Frame
Through completion of follow-up (median follow-up was 23.3 months)

Full study description

brief Summary: The aim of this phase I/II trial is to determine the maximal tolerated dose (MTD) of carfilzomib together with pegylated liposomal doxorubicin hydrochloride (PLD) with or without dexamethasone, and then to establish the efficacy and safety of this novel combination in patients with relapsed or refractory multiple myeloma

Source references

references

citation
Schroeder MA, Fiala MA, Huselton E, Cardone MH, Jaeger S, Jean SR, Shea K, Ghobadi A, Wildes T, Stockerl-Goldstein KE, Vij R. A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 Jul 1;25(13):3776-3783. doi: 10.1158/1078-0432.CCR-18-1909. Epub 2019 Apr 5.
pmid
30952640
type
DERIVED